News & Insights
Crossrail opens – a big day for travellers to and workers in London
At Results Healthcare we execute transactions around the world, with active projects in North America, Europe and Asia Pacific, so we see ourselves as a global organisation with offices and employees in London and New York, so a blog on transport in London might seem oddly parochial, but the opening of Crossrail, or the Elizabeth […]
DCAT’s Back / Back at DCAT
For the first time in forever it felt like the good old days were back in midtown Manhattan at everyone’s favourite pharma supply chain conference The hotels. The meetings. The dinners. Walking up and down Lexington Avenue and bumping into friends and colleagues. It was all happening again at DCAT last week in New York. […]
The growing impact of Environmental, Social, and Governance (“ESG”) on pharmaceutical supply chains.
The Russian invasion of Ukraine has been touted as the final nail in the coffin of globalisation, confirming the nationalisation of key industries and products. With respect to pharmaceutical manufacturing, this is accelerating a trend which has been ongoing for 10 years, the repatriation of drug manufacturing from Asia to the US and Europe has […]
CRO Sector – M&A drivers and market trends – Q1 2022
Whilst the pandemic has caused unprecedented disruption on research and clinical trials, it has also launched the clinical trial landscape into a new area, one with the enhanced utilisation of decentralised trials and the long-awaited embracement of digital technologies to deliver improved patient care, reduced clinical trial costs and speedier outcomes. We have also seen […]
Discovery CROs: what is the “balanced business model” and how is this valued?
Discovery Contract Research Organisations (“CROs”) essentially provide lab-based discovery services such as medicinal chemistry, biological screening etc to pharma companies and biotech, and this business segment has exploded in size, sophistication and value in recent years and is now a focus of both M&A and PE investment. This is covered in our forthcoming white paper […]
Pharma Commercialisation Services Update – February 2022
We are pleased to introduce you to the first of our regular sector updates on the outsourced pharma commercialisation sector. For some time, Results Healthcare has been producing sector updates and whitepapers on the two other major areas pharmaceutical companies choose to outsource: manufacturing and research. This report focuses on commercialisation, encompassing Healthcare Marketing, Market […]
Predictions for Life Sciences Industries for 2022, and no ‘San Francisco’ This Year!
The Covid 19 pandemic continues to have a major impact on the healthcare industry, both positive if you are close to the discovery and provision of treatments for this infection and negative if you are selling certain other drugs, such as antibiotics or providing care services, which have been negatively impacted by this pandemic. However, […]
CDMO Market Update
We are pleased to share with you the CDMO Market Update – November 2021, where we analyse global M&A activity and public market valuations in the CDMO sector. H1 2021 was an exceptional start to the year with 48 deals in total in the CDMO sector, almost reaching the total annual transactions in the previous four […]
The next chapter: Changing market dynamics in commercialisation and medical communications
The last twelve months have been a time of extraordinary activity in the commercialisation sector – the COVID-19 pandemic saw medcomms groups play a crucial part in keeping pharma companies connected with patients and healthcare professionals, and dealmaking was frenetic on both sides of the Atlantic, for smaller agencies as well as for emerging ‘CCOs’. […]
We add value by understanding our sectors inside-out, and we release regular industry research and reports on key trends in the technology and healthcare sectors. Fill out the form to start receiving alerts when we publish new content or to follow our latest deals, upcoming events and company updates.